Several clinical trials are underway with ipilimumab and a human IgG2 anti-CTLA-4 antibody, tremelimumab, alone and in combination with other immunomodulatory antibodies, tumor-targeting antibodies, small molecule therapies and therapeutic cancer vaccines [24, 25]. Here, CTLA4 is linked to neoplasm.